Video
Dr. Pavic on masitinib plus docetaxel in first-line mCRPC
Author(s):
“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.
Video Player is loading.
Body: In this video, Michel Pavic, MD, discusses the background and findings of the study, “Masitinib plus docetaxel as first-line treatment of metastatic castrate refractory prostate cancer: results from study AB12003,” presented recently at the 2021 American Urological Association Annual Meeting. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
